Dec 12
This is part 2 of my article about predictions for the clinical trials industry in 2026. From my reporting on AI growing pains, site-network shakeups, and the never-ending sponsor–site tension over feasibility and budgets, it’s clear the industry is carrying plenty of unresolved business into the new year.
Read the full article featuring Rob DiCicco from Clinical Leader here.
Related Blog Posts
Why Protocol Complexity Keeps Increasing – and How to Fix It
We’ve been discussing simplifying protocol designs for decades. And yet, a phase III protocol today collects nearly 6 million data points on average; a figure that’s been climbing by roughly 11% annually. Read the full article from MedCity News here.
Making AI work where it matters, with Rob DiCicco
In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, for a conversation on the barriers and the breakthroughs in making AI work in drug development and clinical trials. Read the full article featuring Rob DiCicco from Pharmaphorum here.
From Vision to Value: A Blueprint for Implementing Industry Consortia Innovations
Our healthcare landscape is rapidly evolving and presenting us with complex challenges: modernizing clinical trials, ethically integrating artificial intelligence, and delivering patient-centric care. No single organization can tackle these issues alone. Read the full article from DIA Global Forum here.